Rgenix raises $40M in se­ries C fund­ing

BioSpectrum (Asia) - - FINANCE NEWS -

Rgenix, Inc., a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing first-in-class small mol­e­cule and an­ti­body cancer ther­a­peu­tics, an­nounced that it has raised $40 mil­lion in a Se­ries C fi­nanc­ing in support of fur­ther de­vel­op­ment of the com­pany’s clin­i­cal and pre-clin­i­cal on­col­ogy pro­grammes and for gen­eral cor­po­rate pur­poses. The Se­ries C fi­nanc­ing was led by Lepu Med­i­cal, a pub­licly traded global health­care firm, and in­cludes Ocean­pine Cap­i­tal and WuXi Ap­pTec’s Cor­po­rate Ven­ture Fund. Ex­ist­ing in­vestors also par­tic­i­pated in the fi­nanc­ing round, in­clud­ing Novo Hold­ings A/S, Sofinnova Part­ners, Alexan­dria Ven­ture In­vest­ments, LLC, and the Part­ner­ship Fund for New York City’s In­no­vate NY Fund and as­so­ci­ated en­ti­ties. The fi­nanc­ing will support Phase 1b/2 clin­i­cal tri­als of the lead pro­gramme RGX-104 in mul­ti­ple cancer in­di­ca­tions, in­clud­ing in check­point in­hibitor re­frac­tory pa­tients. It will also support early clin­i­cal de­vel­op­ment of RGX-202, a first-in-class cancer me­tab­o­lism pro­gramme, as well as dis­cov­ery stage pro­grammes aris­ing from the Rgenix tar­get dis­cov­ery plat­form.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.